Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma
ConclusionNeoadjuvant chemoimmunotherapy of HNSCC showed high rate of pathological response and low recurrence rate, holding promise for becoming the new standard of care for resectable HNSCC.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Genital Warts | Head and Neck Cancer | HNSCC | Human Papillomavirus (HPV) | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Oral Cancer | Oral Cavity Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study